Production (Stage)
Qualigen Therapeutics, Inc.
QLGN
$3.42
-$0.10-2.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 67.44% | -91.44% | -35.78% | -71.57% | -530.89% |
| Gross Profit | -67.44% | 91.44% | 35.78% | 71.57% | 530.89% |
| SG&A Expenses | 5.73% | -14.33% | -59.35% | -22.76% | -62.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.21% | -54.34% | -51.67% | -46.37% | -33.83% |
| Operating Income | 57.21% | 54.34% | 51.67% | 46.37% | 33.83% |
| Income Before Tax | 65.61% | 44.47% | 58.18% | 37.19% | 31.30% |
| Income Tax Expenses | 214.58% | -- | -130.00% | 28.57% | -1,300.00% |
| Earnings from Continuing Operations | 65.32% | 44.54% | 58.26% | 37.16% | 31.44% |
| Earnings from Discontinued Operations | -100.00% | -- | -236.61% | -- | 100.62% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.07% | 50.93% | 54.49% | 47.15% | 61.55% |
| EBIT | 57.21% | 54.34% | 51.67% | 46.37% | 33.83% |
| EBITDA | 57.24% | 53.31% | 50.83% | 45.20% | 33.80% |
| EPS Basic | 95.35% | 87.02% | 69.76% | 54.60% | 68.98% |
| Normalized Basic EPS | 96.88% | 82.84% | 71.79% | 40.98% | 58.61% |
| EPS Diluted | 95.35% | 87.02% | 69.76% | 54.60% | 69.02% |
| Normalized Diluted EPS | 96.88% | 82.84% | 71.79% | 40.98% | 58.61% |
| Average Basic Shares Outstanding | 651.87% | 284.06% | 50.59% | 19.86% | 23.96% |
| Average Diluted Shares Outstanding | 651.87% | 284.06% | 50.59% | 19.86% | 23.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |